364356-36-5

Basic information

• Product Name: 3-({[2-(methyl-phenyl-amino)-thiazole-4-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 3-({[2-(methyl-phenyl-amino)-thiazole-4-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 364356-36-5
• Molecular Weight: 430.571
• Mol File: 364356-36-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-({[2-(methyl-phenyl-amino)-thiazole-4-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-({[2-(methyl-phenyl-amino)-thiazole-4-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester(364356-36-5)
• EPA Substance Registry System: 3-({[2-(methyl-phenyl-amino)-thiazole-4-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester(364356-36-5)

Safety Data

• Hazardous Substances Data: 364356-36-5(Hazardous Substances Data)

Upstream product

• 364356-34-3 2-(N-methyl-N-phenylamino)thiazole-4-carboxylic acid 
• 140645-24-5 tert-butyl (3S)-3-(aminomethyl)piperidine-1-carboxylate 
• 116574-71-1 tert-butyl (3R)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 103-85-5 monophenylthiourea 
• 25137-01-3 (R)-ethyl nipecotate 
• 161285-05-8 (R)-<<(methylsulfonyl)oxy>methyl>piperidine-1-carboxylic acid tert-butyl ester 
• 155541-67-6 (R)-3-(azidomethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 37675-20-0 (R)-3-hydroxymethyl piperidine 
• 364356-33-2 ethyl 2-(N-methyl-N-phenylamino)thiazole-4-carboxylate 
• 126533-76-4 ethyl 2-(N-phenylamino)thiazole-4-carboxylate 

Relevant articles and documents

Discovery of 2-aminothiazole-4-carboxamides, a novel class of muscarinic M3 selective antagonists, through solution-phase parallel synthesis

Synthesis and structure-activity relationship of a new class of muscarinic M3 selective antagonists were described. In the course of searching for a muscarinic M3 antagonist with a structure distinct from those of the 2-(4,4-difluorocyclopentyl)-2-phenylacetamide derivatives, we identified a thiazole-4-carboxamide derivative (1) as a lead compound in our in-house chemical collection. Since this compound (1) showed relatively low binding affinity (K1 = 140 nM) for M3 receptors in the human binding assays, we tried to improve its potency and selectivity for M 3 over M1 and M2 receptors by derivatization of 1 through a combinatorial approach. A solution-phase parallel synthesis effectively contributed to the optimization of each segment of 1. Thus, we have identified a cyclooctenylmethyl derivative (3e) and a cyclononenylmethyl derivative (3f) as representative M3 selective antagonists in this class.